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ABSTRACT 
ANTONINO CRIVELLO: DNA METHYLATION OF THE INTERFERON-GAMMA 
PROMOTER IN ASSOCIATION WITH OVEREXPRESSION OF THE 
INTERFERON-GAMMA GENE IN PERIODONTAL DISEASE 
(Under the direction of Dr. Shaoping Zhang, Dr. David W. Paquette, Dr. Silvana Barros, 
and Dr. Steven Offenbacher) 
 
The pathogenesis of periodontitis at the biofilm-gingival interface is modulated by 
a cascade of innate immune mechanisms that create a cytokine network. The dental 
biofilm and resultant inflammatory response have the capacity to alter the host DNA 
chromosomal structure through epigenetic mechanisms. The major epigenetic 
modification in humans is DNA methylation. These modifications have the potential to 
permanently alter the local gene expression by inducing tissue localized epigenetic 
changes that can persist within cell lineages and represent a permanently altered gene 
expression pattern that can affect the metabolism of the tissues and the inflammatory 
response. The pro-inflammatory cytokine interferon-gamma (IFN-γ) is an important 
regulator of the innate immune response to oral pathogens.  The objective of this study 
was to compare the level of DNA methylation at the IFN-γ promoter between healthy and 
inflamed gingival tissues and correlate those findings with IFN-γ expression levels. 
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CHAPTER 1 
INTRODUCTION 
Periodontal diseases are amongst the most prevalent inflammatory conditions in 
humans (Oliver et al. 1998). The destruction of the tooth’s attachment apparatus has been 
attributed in part to a microbial etiogoly (Socransky et al. 1998) and to the host’s 
inflammatory response to these periodontopathogens (Offenbacher 1996). The bacterial 
insult at the biofilm-gingival interface results in the direct destruction of host tissues 
through bacterial virulence factors such as collagenases and leukotoxins, and indirectly 
through the activation of host inflammatory cells such as neutrophils and macrophages 
(Offenbacher 1996) which in response to the pathogenic biofilm release effector 
molecules such as prostaglandin E2 (Offenbacher et al. 1994) and proinflammatory 
cytokines such as interleukin-1beta (IL-1β) ( Giannopoulou et al. 2003), tumor necrosis 
factor-alpha (TNF-α) (Ikezawa et al. 2005) and interferon-gamma (IFN-γ) (Dutzan et al. 
2009). These signaling molecules modulate the inflammatory process through the 
autocrine and paracrine activation of inflammatory cells, through mechanisms of 
chemotaxis (Kebschull et al. 2008) and through the regulation of gene expression 
(Trombone et al. 2008). These inflammatory cascades culminate in the clinical 
manifestation of periodontal disease. 
The pro-inflammatory cytokine IFN-γ has been associated with the chronic 
inflammatory lesion with conflicting reports regarding the predominant role of IFN-γ in 
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stable or active periodontal lesion (Takeichi et al. 2000; Lappin et al. 2001). Further 
functions of IFN-γ include a critical role in T-cell differentiation, specifically in T helper 
(Th)1-mediated immunity against viral and bacterial infections (Boehm et al. 1997). Th1 
cells secrete IFN-γ, promoting the containment of the infectious stimulus via, in part 
through macroghage and neutrophil function.  
The expression levels of IL-1α, IL-1β, IL-6, IL-8, TNF-α, Cluster Differentiation 
(CD)14, Toll-Like Receptor (TLR)2, and TLR4 in human gingival fibroblasts were found 
to be significantly higher in inflamed gingival tissues when compared to healthy controls 
when analyzed with DNA microarray analysis (Wang et al. 2003). Microarray analysis 
allows for the evaluation of mRNA expression of numerous genes simultaneously. This 
method of analysis can be used to compare two biological states in order to identify the 
differential expression of genes and related pathways between them. Papapanou et al. 
(2004) examined the gene expression profile of gingival tissues from 14 patients with 
chronic and aggressive periodontitis by microarray analysis. These authors reported 
differences in gene profiling between diseased and healthy sites within the same patient 
while no significant differences were noted between the gene expression signature of 
patients with aggressive and chronic periodontitis in this pilot study (Papapanou et al. 
2004). Recently, IFN-γ gene expression was found to be upregulated in patients with 
chronic periodontitis (Gomes et al. 2006). 
The role of epigenetics in the inflammatory response has been studied. 
Epignenetic modifications are regulatory mechanisms that do not involve the direct 
modification of the intrinsic nucleotide sequence information encoded within the DNA. 
Instead, they can involve alterations of nucleosomal histone proteins and of cytosine 
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residues in the DNA sequence. The methylation of DNA at cytosine-guanine (CpG) 
dinucleotides is a postreplication event catalyzed by DNA (cytosine-5)-methyltransferase 
(Rao et al. 2000) through the recognition of established methylation patterns during 
embryogenesis and reproduction of these patterns during the replication of adult cells 
(Razin et al. 1994). Genes that are active in a particular tissue or cell type tend to 
demonstrate decreased methylation of CpG dinucleotides, while those that are inactive 
are often characterized by a dense CpG methylation pattern (Rao et al. 2000). 
Hypomethylation of the proximal promoter region of the IFN-γ gene has been correlated 
with increased transcription of the gene product in human Th1 cell clones; 
hypermethylation of this region has been demonstrated to inhibit nuclear factor binding to 
the promoter region with an associated decrease in transcription (Young et al. 1994). 
Previous studies using methylation-sensitive restriction mapping techniques have 
identified significant CpG methylation sites within the IFN-γ promoter region. Several 
groups have studied CpG sites within the IFN-γ promoter that have been demonstrated to 
be associated with the epigenetic regulation of Th cell differentiation (White et al. 2002; 
White et al. 2006; Kwon et al. 2008). Frequently evaluated sites include those at positions 
-295, -186, -54, +122, +128 and +171 with respect to the start of transcription within the 
IFN-γ gene. 
Epigenetic modifications are associated with chronic inflammatory conditions 
including rheumatoid arthritis and diabetes mellitus (Backdahl et al. 2009). Recently, it 
has been demonstrated in an animal model that the periodontal pathogens found in the 
dental biofilm and the subsequent inflammatory response also have the capacity to alter 
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the host DNA chromosomal structure through epigenetic mechanisms (Bobetsis et al. 
2007).  
The objective of this study is to characterize the DNA methylation pattern of the 
IFN-γ promoter region in healthy and periodontally-involved human gingival tissues and 
to assess differences in the mRNA expression levels between these “healthy” / non-
inflamed and “diseased” / inflamed tissues. 
  
CHAPTER 2 
MATERIALS AND METHODS 
Study Population 
Following protocol approval by the University of North Carolina Institutional 
Review Board (IRB) at the University of North Carolina at Chapel Hill, gingival biopsy 
samples from 10 non-periodontitis (“healthy” / “non-inflamed” or minimally-inflamed) 
and 10 chronic periodontitis (“diseased” / “inflamed”) sites were collected from 20 
different subjects. The “inflamed” (periodontitis) tissues were collected from sites 
demonstrating probing depths of 5 millimeters (mm) or greater, bleeding on probing and 
severe radiographic alveolar bone loss. “Non-inflamed” (non-periodontitis) gingival 
tissue was collected from sites with probing depths of 4 mm or less, no bleeding on 
probing and no radiographic evidence of bone loss. “Non-inflamed” tissue samples were 
collected during crown lengthening procedures while gingiva from the periodontally-
involved sites was obtained during periodontal flap surgery. The inclusion criteria 
included subjects being adult males or females between the ages of 18 and 65 years 
(inclusive), having at least 20 teeth in the functional dentition, excluding third molars and 
that the subjects were in good general health. Exclusion criteria included individuals with 
a chronic disease presenting with oral manifestations, subjects exhibiting gross oral 
pathology, treatment with antibiotics for any medical or dental condition within 1 month 
prior to the screening examination, chronic treatment (i.e., two weeks or more) with any 
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medication known to affect periodontal status (e.g., phenytoin, calcium channel blockers, 
cyclosporin, coumadin, non-steroidal anti-inflammatory drugs) within one month of the 
study, ongoing medications initiated less than three months prior to the study (i.e., 
medications for chronic medical conditions must have been initiated at least three months 
prior to the study).  
             DNA Isolation and Sodium Bisulfite Conversion 
Genomic DNA was isolated from collected gingival tissue samples using a 
DNeasy Mini Kit (Qiagen, Valencia,CA) according to the manufacturer’s instructions. 
Genomic DNA was bisulfite treated using established procedures (Grunau et al. 2001). 
Briefly, 1 µg of genomic DNA in 45 µl of nuclease-free water was denatured at 42°C for 
20 minutes with 5 µl of freshly prepared 3 M sodium hydroxide (NaOH). Saturated 
sodium bisulfite solution (5.20-5.69M) was freshly prepared by adding 5.4 g of sodium 
bisulfite to 8 ml of water and the pH adjusted to a final pH of 5 with the addition of 1.3 
ml of a 3 M NaOH solution. Hydroquinone (0.22 g; Sigma H-9003) was dissolved in 10 
ml of water and 500 µL of this solution was added to the dissolved sodium bisulfite 
solution resulting in a final concentration of 10 mM. 450 µl of the bisulfite-hydroquinone 
solution was added directly to the denatured DNA and the reaction was performed in the 
dark water bath at 55°C overnight. The DNA was then desulfonated using Wizard DNA 
Clean-up Systems (Promega) according to the manufacture’s protocol and resolved in 50 
µl of 1 mM Tris-Cl pH 8. This solution was combined with 5.5 µl of a 3 M NaOH 
solution and incubated at 37°C for 20 minutes. The DNA was then neutralized with 40 µl 
of a 7.5 M ammonium acetate solution, precipitated with 300 µl of 100% ethanol and 2 µl 
of seeDNA. After overnight incubation at -20°C, the DNA was precipitated and washed 
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with 500 µl of 70% ethanol and dried. The DNA was finally resolved in 25 µl of 1mM 
Tris-Cl pH 8 and stored at -20°C. 
Amplification 
The detailed information of primers/sequencers used in PCRs can be found in 
Table 1. Five amplicons containing 6 CpG sites within the promoter region of IFN-γ were 
included in the methylation analysis. Individual PCR condition can be found in Table 2. 
 
 
Table 1: Primers/sequencers for amplification of bisulfate-treated DNA samples. 
CpG site position Primers Sequences 
Position -295 
Forward 5’-[Biotin] 
TTTGTAAAGGTTTGAGAGGTTTTAGAAT-3’ 
Reverse 5’-CAAACCCATTATACCCACCTATACCA-3’ 
Sequencer 5’-TTTTATACCTCCCCACTT-3’ 
Position -186 
Forward 5’-TTAGAATGGTATAGGTGGGTATAATGG-3’ 
Reverse 5’-[Biotin] 
TATTATAATTAAAATTTCCTTTAAACTCCT-3’ 
Sequencer 5’-GGGTATAATGGGTTTGTT-3’ 
Position -54 
Forward 5’-GGGTTTGTTTTATAGTTAAAGGATTTAAGG-3’ 
Reverse 5’-[Biotin] 
AATCAAAACAATATACTACACCTCCTCTAA-3’ 
Sequencer 5’-TATTTTATTTTAAAAAATTTGTG-3’ 
Position +171 
Forward 5’- [Biotin] 
TTTTGGATTTGATTAGTTTGATATAAGAA-3’ 
Reverse 5’- CATTTTCAACCACAAACAAATACTATTAA-3’ 
Sequencer 5’- ACAACCAAAAAAACCC-3’ 
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CpG site position Primers Sequences 
Position +122-128 
Forward 5’-[Biotin] 
TTTTGGATTTGATTAGTTTGATATAAGAA-3’ 
Reverse 5’-AAAACCCAAAACCATACAAAACTAAAA-3’ 
Sequencer 5’-CTAAAAAACCAAAATATAACTTAT-3’ 
 
Table 2: PCR conditions. 
 Cycles      (x45)  
Amplicons Denaturation Denaturation Annealing Elongation Elongation 
Step 
CpG site T(oC),T(min) T(oC),T(min) T(oC),T(min) T(oC),T(min) T(oC),T(min) 
-295 94,15 94,30 58,30 72,30 72,10 
-186 94,15 94,30 54,30 72,30 72,10 
-54 94,15 94,30 60,30 72,30 72,10 
+122 +128 94,15 94,30 55,30 72,30 72,10 
+171 94,15 94,30 55,30 72,30 72,10 
 
Pyrosequencing 
PCR products (5-20 µL) were added to a mix consisting of 2 µL Streptavidin 
Sepharose HP™ (Amersham Biosciences), 40 µL binding buffer (Biotage) and high 
purity water to achieve a total volume of 82 µl. This mixture was shaken at 1200 rpm for 
5 minutes at room temperature. Vacuum Prep Tool™ (Biotage) was used to prepare 
single-stranded PCR products according to the manufacturer’s instructions. The 
Sepharose beads with the single stranded templates attached were then released into a 
PSQ 96 Plate Low™ (Biotage) containing 12 µL annealing buffer (Biotage) with 0.25 
µM corresponding sequencer (Table 1). Pyrosequencing reactions were performed in a 
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PSQ 96MA™ System (Biotage) according to the manufacturer’s instructions, with the 
PyroGold SQA™ Reagent Kit (Biotage). CpG site quantification was performed with 
methylation Software PyroQ-CpG™. Criteria for Pyrogram selection were as follows: 
sufficient peak height of >15 units (arbitrary units for light emission calculated by the 
software), symmetric peaks without any irregularities or side-peaks, wide reading length 
with a high reliability until the end of the sequence, and absence of any significant signals 
at the positions where a bisulfite treatment control was included or where control 
nucleotides were dispensed to check for unspecific background signals. 
Statistical Analysis 
The Wilcoxon Ranked Sum test was used for the comparison of median 
methylation levels of all CpG sites observed within each sample group and the resulting 
p-values were plotted against the start point of the window. The threshold for statistical 
significance was set at a p-value less than 0.05. All analyses were performed using SAS 
v.9.2. (SAS Institute, Cary, NC). 
Quantitative Real Time PCR  
Total RNA was isolated from all gingival tissues (n=20) with the use of the 
RNeasy Mini Kit (Qiagen, Valencia, CA ). cDNA from 2 µg of total RNA was 
synthesized using the Omniscript Kit (Qiagen) and random decamer primers. Real-time 
PCR was performed with 1 µl cDNA, 12.5 µl TaqMan Universal PCR mix, and 1.25 µl 
20X Assay on demand gene expression assay mix  (Mm00445273_m1 from Applied 
Biosystems, Foster City, CA), in a 7000 Sequence Detection System (ABI Prism, 
Applied Biosystems). Reactions were performed in duplicates and at two independent 
times. The ribosomal 18s (housekeeping gene) was used as an endogenous control. 
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Results were evaluated using the delta–delta Ct method, where delta Ct was calculated as 
(IFN-γ Ct) - (18s Ct), and the relative quantity of IFN-γ mRNA expression was 
calculated by the delta–delta Ct as 2-[(infected sample delta Ct)-(control sample delta Ct)]. 
 
 
 
 
 
 
 
  
CHAPTER 3 
RESULTS 
        A lower level of methylation was found at the six evaluated CpG sites within the 
IFN-γ promoter region of the “inflamed” gingival tissues compared to “healthy” samples. 
Figure 1 demonstrates two representative pyrograms of the methylation status of the IFN-
γ promoter region at position -295 from healthy and periodontally-involved gingival 
tissue samples indicating that 56% of the amplification products from “healthy” tissue 
taken from 1 subject were methylated at position -295 (Figure 1A) while 34% of the PCR 
products from “diseased” tissue taken from 1 subject were methylated at position -295 
(Figure 1B). 
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Pyrograms of the IFN-γ Promoter Region at Position -295 
From Healthy and Periodontally-Involved Gingival Tissues 
 
 
 
Figure 1: The pyrograms illustrate a control and test sample. Methylation levels of the 
CpG site at position -295 in the “non-inflamed” and “inflamed” gingival tissues analyzed 
with the Pyro Q-CpG system.  
A) 56% of the amplification products from “non-inflamed” gingival tissue were 
methylated B) 34% of the PCR products from “inflamed” gingival tissue were 
methylated.  
A 
B 
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Table 1 illustrates the mean percentage (%) of DNA methylation and standard deviations 
(s.d.) at the evaluated 6 CpG positions within the IFN-γ promoter for the non-
periodontitis and periodontitis groups.  
 
Table 3: The mean % DNA methylation, standard deviation (s.d.) and statistical 
significance at the six CpG positions within the IFN-γ promoter region for the non-
periodontitis and periodontitis tissue samples. 
Periodontal Status / 
CpG Position 
Non-Periodontitis Periodontitis Statistical 
Significance 
% DNA Methylation  
(Mean +/- s.d.) 
% DNA Methylation 
(Mean +/- s.d.) 
p-value 
-295 52.5 +/- 5.7 42.7 +/- 9.7 0.002 
-186 35.4 +/- 7.8 33.6 +/- 5.9 0.84 
-54 59.7 +/- 4.6 58.0 +/- 6.1 0.55 
+122 71.0 +/- 8.6 63.1 +/- 11.5 0.01 
+128 74.9 +/- 4.4 71.1 +/- 7.7 0.03 
+171 51.9 +/- 3.1 48.0 +/- 2.6 0.03 
 
Figure 2 demonstrates the relative levels of methylation at the 6 CpG sites for 
periodontitis and non-periodontitis tissues. The average percentage methylation for 
positions -295, -186, -54, +122, +128 and +171 for the non-periodontitis gingival tissues 
were 52.5%, 35.4%, 59.7%, 71.0%, 74.9% and 51.9%, respectively while for the 
periodontitis samples, the percentage methylation for the same positions were 42.7%, 
33.6%, 58.0%, 63.1%, 71.1% and 48.0%, respectively. The difference in the level of 
methylation was statistically significant for nucleotide positions -295 (p=0.002), +122 
(p=0.01), +128 (p=0.03) and +171 (p=0.03) but not significant for positions -186 
(p=0.84) and -54 (p=0.55).   
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Figure 2: The percentage of methylation in each individual CpG site from periodontitis 
and non-periodontitis gingival tissues. Methylation levels were consistently lower at all 
of the evaluated CpG sites within the IFN-γ promoter region in the periodontitis tissues 
when compared to the non-periodontitis samples. 
 
The overall level of methylation for the IFN-γ promoter was statistically 
significantly (p=0.01) lower for the periodontally-involved gingival samples (Figure 3). 
For the non-periodontitis samples, the median percent methylation value was 57% with a 
maximum value of 87% and a minimum value of 25% methylation. The median percent 
methylation for the periodontitis gingival samples was 51.5% with a maximum of 84% 
and a minimum of 22%.   
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Figure 3: Box plots demonstrating the overall level of methylation of the examined CpG 
sites within the IFN-γ promoter from non-periodontitis and periodontitis gingival tissues.  
 
The level of mRNA expression was greater for “inflamed” tissues than “non-
inflamed” tissues with the difference not statistically significant (p=0.28). The healthy 
“non-inflamed” gingival tissues demonstrated a 1.6 +/- 0.5 fold increase in mRNA 
expression while the “inflamed” periodontal tissues had an increase in IFN-γ mRNA 
expression of 2.4 +/- 0.6 fold relative to periodontally-healthy gingival samples      
(Figure 4). The gingival tissues from the periodontitis group had a 1.6 fold increase in 
IFN-γ gene expression compared to the healthy gingival control. 
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Figure 4: The levels of mRNA expression between the periodontitis and non-periodontitis 
samples demonstrated a relatively greater level of expression from the “inflamed” tissues. 
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CHAPTER 4 
DISCUSSION 
        Differential methylation patterns within the IFN-γ promoter region between diseased 
periodontal tissues and healthy gingiva were associated with differing levels of IFN-γ 
gene expression. In this study, periodontally-involved human gingival tissue samples 
were consistently hypomethylated relative to healthy gingival samples with respect to 
CpG sites within the IFN-γ promoter. Overall, the promoter region of periodontally-
inflamed tissues was relatively hypomethylated. Furthermore, the level of mRNA 
expression of the IFN-γ gene tended to be greater for “inflamed” tissues than “non-
inflamed” healthy tissues. 
Periodontitis is an infectious chronic inflammatory state with demonstrable levels 
of pro-inflammatory cytokines at a systemic level in serum and locally in gingival tissues 
and in gingival crevicular fluid (GCF). The levels of IL-1β, TNF-α and IFN-γ have all 
been found to be significantly elevated in serum samples, gingival tissue biopsies and 
GCF from periodontitis patients (Stashenco et al. 1991; Lee et al. 1995; Gorska et al. 
2003). Recently, Dutzan et al. demonstrated higher cytokine IFN-γ levels in the GCF and 
greater IFN-γ expression in gingival tissues from progressive periodontal lesions in 
patients with chronic periodontitis (Dutzan et al. 2009). 
The production of IFN-γ promotes the phagocytic containment of the infectious 
stimulus via containment through macroghage and neutrophil function. The neutrophil is 
the primary effector cell in the inflammatory response to the bacterial biofilm 
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(Offenbacher 1996). The peripheral blood neutrophils isolated from patients with both 
chronic (Fredriksson et al. 2003) and aggressive (Gronert et al. 2004) forms of 
periodontal disease have been characterized as demonstrating a hyperactive phenotype 
termed hyperresponsivity. These hyperresponsive neutrophils have been proposed to 
elicit a component of the tissue damage seen in periodontal diseases. Wright et al. noted 
an increased expression of a significant number of IFN-stimulated genes from 
hyperresponsive peripheral blood neutrophils isolated from chronic periodontitis patients 
relative to periodontally healthy controls (Wright et al. 2008). Elevated peripheral blood 
type I IFN levels in periodontitis patients demonstrated the potential to serve as a priming 
factor that could contribute to neutrophil hyperresponsivity with respect to FcγR-
mediated reactive oxygen species (ROS) generation (Matthews et al. 2007). IFN-γ has 
also been shown to “prime” for neutrophil ROS generation (Ellis et al. 2004).  
The immune response includes a family of pattern-recognition receptors called 
Toll-like receptors (TLRs) that recognize pathogen-associated molecular patterns which 
are highly conserved structures present in large groups of microorganisms (Takeda et al. 
2005). Bacterial lipopolysaccharide, peptidoglycan, bacterial DNA and double-stranded 
RNA are all examples of pathogen-associated molecular patterns (Rangsini et al. 2007). 
TLRs are predominantly expressed on cells of the innate immune system including 
neutrophils, monocytes/macrophages and dendritic cells. They are also present on 
gingival epithelial cells (Kusumoto et al. 2004). Ligand binding to TLRs initiates a 
cascade of signaling pathways that lead to the transcription of pro-inflammatroy 
cytokines involved in the inflammatory response to the dental biofilm (Rangsini et al. 
2007). TLR2 and TLR4 have been well documented and are associated with the 
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recognition of pathogen-associated molecular patterns in the lipopolysaccharide and 
fimbriae from Porphyromonas gingivalis and the lipopolysaccharide from 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans and Fusobacterium 
nucleatum, respectively (Hirschfeld et al. 2001; Asai et al. 2001; Darveau et al. 2004; 
Mochizuki et al. 2004; Yoshimura et al. 2002). Uehara et al. demonstrated that 
expression of TLR4 on human gingival epithelial cells could be enhanced by treatment 
with IFN-γ (Uehara et al. 2002). The expression of CD14 (a TLR-related molecule: a co-
receptor for lipopolysaccharide) is up-regulated in human gingival fibroblasts upon 
increased production of IFN-γ in inflamed periodontal tissues (Mochizuki et al. 2004). 
Upon stimulation with Salmonella enteric and Aggregatibacter actinomycetemcomitans 
lipopolysaccharide, IFN-γ-primed CD14 human gingival fibroblasts demonstrated 
increased production of the neutrophil recruiting chemokine, IL-8 via the enhanced 
CD14-TLR4 system (Tamai et al. 2002; Mochizuki et al. 2004).  
Overexpression or prolonged production of IFN-γ may lead to direct host tissue 
destruction or indirect destruction through the activation of effector cells such as the 
macrophage (Boehm et al. 1997). IFN-γ stimulation of macrophages induces direct 
antimicrobial mechanisms as well as up-regulation of antigen processing and presentation 
pathways (Schroder et al. 2004). The effects of IFN-γ on bone metabolism have been 
contradictory. There is evidence to support an inhibitory function for IFN-γ with respect 
to the proliferation and differentiation of committed precursor cells into osteoclasts 
(Takayanagi et al. 2000). IFN-γ suppresses osteoclastogenesis by interfering with the 
receptor activator of nuclear factor κB ligand/receptor activator of nuclear factor κB 
(RANKL/RANK) signaling pathway indirectly by inducing the degradation of the RANK 
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adaptor protein, TNF receptor-associated factor 6, resulting in a strong inhibition of 
RANKL transcription (Takayanagi et al. 2000). Opposing evidence exists to support a 
decrease in the amount of trabecular bone and mineralization in osteoporotic mice with 
respect to elevated IFN-γ levels (Mann GN et al. Endocrinology 1994). IFN-γ is the 
physiologic inducer of the Major Histocompatability Complex (MHC) II expression and 
thus of antigen presentation and consequently, IFN-γ leads to T cell activation and T cell 
secretion of the osteoclastogenic factors RANKL and TNF-α (Gao et al. 2007). IFN-γ has 
both direct and indirect anti-osteoclastogenic and indirect pro-osteoclastogenic properties 
in vivo. Gao et al. demonstrated that under conditions of estrogen deficiency, infection, 
and inflammation the in vivo effects of IFN-γ in a mouse model were of 
osteoclastogenesis and bone resorption (Gao et al. 2007).  
The immune response to periodontopathic bacteria is in part determined by the 
balance between Th1 and Th2 cells (Gemmell et al. 2007). The division of Th cells into 
functional subsets is regulated by differential cytokine secretion (Mosmann et al. 1986). 
Th1 cytokines include IL-2, IL-12 and IFN-γ and culminate in a cell mediated response 
while the Th2 cytokines include IL-4, IL-5, IL-6, IL-10, and IL-13 and potentiate 
humoral immunity (Modlin et al. 1993). Th1 cells secrete IFN-γ and thereby activate 
macrophages, natural killer cells and CD8+ T-cells. Several studies have demonstrated a 
predominant Th1 cell response in the stable periodontal lesion and favor a Th2 cell 
response in active lesions (Lappin et al. 2001). Conflicting results have shown a 
predominance of Th1 cells or a reduction of Th2 cells in tissues demonstrating disease 
progression (Takeichi et al. 2000). Recent studies report the involvement of both Th1 and 
Th2 cells in periodontal disease sites (Prabhu et al. 1996). In a mouse model, both Th1 
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and Th2 cytokine knockout mice exhibited significantly more natural alveolar bone loss 
than their respective wild-type control mice with IFN-γ knockout mice demonstrating a 
two-fold increase in alveolar bone loss compared with wild-type control mice (Ivanovski 
A et al. 2007). The progression of gingivitis to periodontitis is accompanied by a shift 
from a predominantly T-cell lesion to a B-cell lesion (Page et al. 1976) so that it can be 
extrapolated that a shift from a predominantly cell-mediated immunity (Th1) to humoral 
immunity (Th2) occurs during the pathogenesis of periodontitis. It has been suggested 
that a susceptibility factor in the development of periodontitis may reside with T 
regulatory cells and whether they produce Th1 or Th2 responses to the bacterial biofilm 
(Kinane et al. 2007). Kikuchi et al. demonstrated that Aggregatibacter 
actinomycetemcomitans lipopolysaccharide-stimulated human monocyte-derived 
dendritic cells stimulated Th1 differentiation via IL-12 production (Kikuchi et al. 2004).  
IFN-γ is the prototypical Th1 cytokine and is expressed from a locus which also 
contains genes encoding members of the IL-10 family located on chromosome 12 in 
humans (Bowen H et al. 2008). During Th1 cell differentiation, IL-12 signals via the IL-
12R/STAT4-signalling pathway to induce IFN-γ expression. The secreted IFN-γ signals 
through the IFN-γR/STAT1 pathway to further increase IFN-γ levels resulting in a 
positive autoregulatory loop reinforcing Th1 differentiation. Transcription factors 
regulate gene expression by directly or indirectly being recruited to regulatory regions 
within a gene. The IFN-γ promoter contains multiple potential transcription factor 
binding domains for notably the activator protein 1 (AP1), cAMP response element 
binding protein (CREB) and YY1 (White GP et al. 2002).  
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Honda et al. compared the gene expression profile of inflammatory mediators 
including IFN-γ in gingivitis and periodontitis lesions. IFN-γ expression was 
demonstrated to be elevated in the periodontitis group (Honda et al. 2006). Gomes et al. 
evaluated the levels of mRNA expression in controlled diabetics with moderate and 
severe chronic periodontitis and found elevated levels of IFN-γ mRNA in two out of 
thirteen patients (15.4%) with moderate chronic periodontitis and five out of ten patients 
(50%) with severe chronic periodontitis (Gomes et al. 2006). 
One recognized mechanism for gene regulation is the epigenetic regulation of 
gene expression which involves changes in nucleosomal histones and nucleotide residues 
in the DNA sequence (Rao et al. 2006). The methylation of DNA at cytosine residues 
within CpG dinucleotides is the major epigenetic modification found in humans. 
Transcribed or “active genes” within particular tissues or cells tend to be relatively 
hypomethylated while those that are not being readily transcribed, or “inactive genes” are 
often relatively hypermethylated (Rao et al. 2006). These modifications determine the 
level of cell type-specific gene transcription by modulating the accessibility of 
transcription factors, coactivator proteins, basal transcription apparatus, and RNA 
polymerase II to the gene promoter region (Rao et al.). Since most DNA methylation 
changes are not readily reversed and are usually conserved following DNA replication, 
these modifications have the potential to permanently alter the local gene expression by 
inducing local tissue-level epigenetic changes that can persist within cell lineages and 
represent a permanently altered gene expression pattern that can affect metabolism of the 
tissues and inflammatory responses (Rao et al. 2006).  
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Chronic inflammation is associated with genetic and epigenetic modifications 
(Stenvinkel et al. 2007; Backdahl et al. 2009). Genetic differences exist in the extent of 
the inflammatory response based on the levels of expression of inflammatory mediators 
such as IL-1 and TNF-α (Schenkein et al. 2002). Genetic polymorphisms in several genes 
have been demonstrated to affect the immune and inflammatory response to microbial 
insults and are associated with an increased risk for chronic and aggressive forms of 
periodontal disease. The IFN-γ gene contains a microsatellite polymorphism in its first 
intron. Two single nucleotide polymorphisms (SNPs) in this gene [Intron1 (760 T or A) 
and 30 (G or A)] combine with the microsatellite polymorphism to form two major 
haplotypes, I and II (Vandenbroeck et al. 2003). Homozygotes for alleles found on 
haplotype I produced 1.5–3.0 times more IFN-γ than did homozygotes for marker alleles 
on haplotype II (Hutchings et al. 2002). Lymphocytes from patients with tuberculosis 
stimulated with a disease-related antigen (Mycobacterium tuberculosis purified protein 
derived (PPD) antigen) demonstrated elevated levels of IFN-γ production in haplotype I 
versus haplotype II carriers over a course of more than six months (Lopez-Maderuelo et 
al. 2003). 
Epigenetic modifications have been associated with systemic conditions. DNA 
methylation has been correlated to varying degrees with cancer (Laird 2005), diabetes 
mellitus (Poirier et al. 2001; Ling et al. 2008), atherosclerosis (Hiltunen et al. 2003) and 
rheumatoid arthritis (Takami et al. 2006). DNA methylation in human peripheral blood 
cells from chronic kidney disease patients correlated with different degrees of 
inflammation classified by C-reactive protein (CRP) levels (Stenvinkel et al.2007). The 
association between chronic inflammation and DNA methylation exists both in the 
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presence and absence of microbial infection (Shames et al. 2007). Maekita et al. analyzed 
the effect of H. pylori infection on the quantity of methylated DNA molecules within 
eight regions of seven CpG islands in noncancerous gastric mucosae and examined its 
association with gastric cancer risk (Maekita et al. 2006). Gastric mucosae were collected 
from 154 healthy volunteers (56 H. pylori-negative and 98 H. pylori-positive) and 72 
cases with differentiated-type gastric cancers (29 H. pylori-negative and 43 H. pylori-
positive) by endoscopy. Among healthy subjects, methylation levels of all the eight 
regions were 5.4 to 303-fold higher in H. pylori-positives than in H. pylori-negatives (p < 
0.0001). Methylation levels of the LOX, HAND1, and THBD promoter CpG islands and 
p41ARC exonic CpG island were as high as 7.4% or more in H. pylori-positive 
individuals. Among H. pylori-negative individuals, methylation levels of all the eight 
regions were 2.2- to 32-fold higher in gastric cancer cases than in age-matched healthy 
volunteers (p ≤ 0.01). Among H. pylori-positive individuals, methylation levels were 
highly variable, and that of only HAND1 was significantly increased in gastric cancer 
cases (1.4-fold, p = 0.02). The group concluded that H. pylori infection potently induced 
methylation of CpG islands and that methylation levels of specific CpG islands in 
noncancerous gastric mucosae may be associated with gastric cancer risk in H. pylori –
negative individuals. (Maekita et al. 2006). Distant infection with oral microorganisms 
has been demonstrated to lead to epigenetic alterations. Bobetsis et al demonstrated using 
a mouse model that pregnant mice exposed to infection with C. rectus, presented 
epigenetic modification in a promoter region of the insulin-like growth factor -2 (igf2) 
gene with specific increases in DNA methylation that played a critical role in IGF2 
expression and subsequent fetal growth (Bobetsis et al. 2007). 
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In the present investigation, lower levels of methylation were found at all six CpG 
sites within the IFN-γ promoter for the periodontally-involved tissues compared to the 
healthy controls (Figure 2). The promoter region was relatively hypomethylated in 
“inflamed tissues” (Figure 3). IFN-γ mRNA expression levels for the periodontally-
involved tissues were greater than for the “non-inflamed” samples (Figure 4). Potential 
transcription factor binding domains within the IFN-γ promoter region include the 
activator protein 1 (AP1), cAMP response element binding protein (CREB) and YY1 
(White GP et al. 2002). Methylation of CpG sites corresponding to these regulatory 
regions could potentially affect the transcription of the IFN-γ gene. The decreased level 
of methylation within the promoter region of the IFN-γ gene seen in inflamed periodontal 
tissues allowed for greater expression of IFN-γ transcripts and consequently a greater 
expression of the pro-inflammatory cytokine within “diseased” tissues. It is hypothesized 
that the relatively hypomethylated state of the promoter region allows for more nuclear 
factor binding and promotion of transcription. Consequently, these findings demonstrate 
that inflamed periodontal tissues are hypomethylated compared to healthy gingival 
tissues within the IFN-γ gene promoter and subsequently produce more transcripts and 
accordingly more IFN-γ at the tissue level, findings consistent with reports of elevated 
levels of IFN-γ in the gingival tissues from progressive periodontal lesions in patients 
with chronic periodontitis (Dutzan et al. 2009). Approximately half of the CpG islands in 
the genome are not associated with annotated promoters, but are intra- or intergenic 
(Delcuve et al. 2009). These CpG islands may be associated with the transcriptional 
regulation of non-coding RNAs (Illingworth et al., 2008) as has been documented in 
various tumors demonstrating an abnormal expression of numerous micro RNAs 
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(miRNAs) linked to abnormal DNA methylation (Guil et al. 2009). miRNA are 
regulatory molecules that contribute to differential gene expression. Meng et al. 
demonstrated that the differential expression of a specific miRNA was associated with 
tumor cell growth in cholangiocarcinoma (Meng et al. 2008). The group recognized that 
overexpression of IL-6 was associated with an increased methylation activity via 
upregulation of expression of DNA methyltransferase enzyme DNMT-1. Further, 
miRNA expression profiling indicated that miRNA were aberrantly expressed in a 
methylation-dependent manner by IL-6 and that this differential expression of the 
miRNA was associated with tumor cell growth involving the mitogen-activated protein 
kinase (MAPK) cascade (Meng et al. 2008). As such, a mechanism was identified by 
which inflammation-associated cytokines may epigenetically modulate gene expression 
through DNA methylation of CpG islands not associated with annotated promoters and 
contribute to tumor biology.  
The findings from this study imply a potential role for the epigenetic modification 
of genomic DNA in the pathogenesis of chronic inflammatory periodontal disease. 
Differential levels of methylation of the IFN-γ promoter region demonstrated differences 
in IFN-γ gene expression in diseased periodontal tissues in comparison to healthy 
gingiva. The evaluation of DNA methylation patterns of known inflammatory and anti-
inflammatory genes may serve as a potential diagnostic tool in adjunct with current 
methods of diagnosing periodontal disease. With further research, it will be interesting to 
assess if these markers precede the clinical signs of periodontitis and allow for the 
detection of early and progressing lesions or the identifications of patients at a greater 
risk for periodontitis. Indications of this may be inferred by the fact that in this study, 
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clinically healthy sites demonstrated a baseline level of methylation at the IFN-γ 
promoter and that epigenetic control may be dose dependent. The modulation of DNA 
methylation as a means to regulate the inflammatory response to periodontal pathogens 
and subsequent destruction of the tooth’s attachment apparatus is a potentially interesting 
therapeutic modality for the management of periodontal disease. To date, the majority of 
research has been tailored to the development of demethylating epigenetic drugs in an 
effort to reactivate tumor suppressor genes. Hypermethylated targets have demonstrated 
therapeutic potential, notably in the treatment of cancer with the advent of inhibitors of 
DNA methyltransferases that restore the expression of pathologically silenced genes such 
as tumor suppressor genes. The prototype inhibitors of DNA methylation are the 
nucleoside analogues 5-aza-CR and 5-aza-CdR which are incorporated in place of 
cytosine into replicating DNA resulting in the formation of heritable demethylated DNA. 
Further studies are required to better understand the role of DNA methylation in 
periodontal inflammation.  
 
 
 
 
 
  
PART II: 
CLINICAL TRIAL OF A 2.5% CHLORHEXIDINE DIACETATE INTRAORAL 
DELIVERY SYSTEM. PHASE II: A REPORT ON RECRUITMENT AND 
SAFETY OUTCOMES 
 
CHAPTER 1 
INTRODUCTION 
Chlorhexidine (CHX) is a broad spectrum antimicrobial agent with demonstrated 
activity against both Gram-negative and Gram-positive bacteria, yeast, fungi, and viruses 
(Hugo et al. 1964; Matisheck et al. 1978; Hiom et al. 1992; Harrison et al. 1998). The 
delivery of CHX at therapeutic doses at a constant rate over an extended period of time is 
desirable for the treatment of chronic periodontal conditions. A novel intraoral delivery 
system has incorporated 2.5% (by weight) chlorhexidine diacetate (CDA) into an 
ethylene vinyl acetate (EVA) mouthguard and has demonstrated sustained concentrations 
of chlorhexidine for up to 14 days (Tallury et al. 2007).  
A recent single-center, 5-week, open-label trial evaluated six medically healthy 
subjects with generalized moderate plaque-induced gingivitis who wore the EVA 
delivery system 12 hours per day for 21 days in the maxillary arch (Van Scoyoc et al. 
2008). The group found that all patients tolerated the delivery system with 18 non-severe 
adverse events (AEs) recorded. All AEs were categorized as Grade 1 according to the 
Common Terminology Criteria for Adverse Events (CTCAE) v3.0 scale. The most 
frequently reported AEs were oral lesions. There were nine lesions in three subjects. Six 
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of the lesions were categorized as “unlikely related” or “not related” to the mouthguard 
due to patients reporting a history of recent non-specific oral trauma. Three lesions were 
categorized as “likely related” to the study mouthguard, and all three ulcerations 
werereported in the same subject over a 1 month time period. No treatment was required 
for any of the oral lesions, and all lesions resolved upon completion of the study. The 
second most reported AE was headache (7 reports in 3 subjects) and graded as either “not 
related” or “unlikely related” to the study mouthguard. The remaining two AEs were 
hematomas attributed to venipuncture, and no treatment was required. The delivery 
system did not appear to increase calculus or intra-oral discoloration indices. No 
significant changes in blood chemistries, hematology or urinalysis occurred during the 
course of the study. Ninety-four percent of serum samples had levels of CDA below the 
detectable limit of 0.010 µg/ml, and all samples were ≤ 0.012µg/ml. Over the 21-day 
course of treatment, salivary CDA levels increased two hours post-dosing at all time 
points. Analysis of covariance revealed a significant decrease in mean pocket depth in the 
maxillary arch over 21 days (p<0.05) when controlling for changes in the mandibular 
arch. The group concluded that CDA was released from the EVA polymer over 21 days 
of dosing and that this drug delivery system was safe for human use with minimal 
systemic exposure. The group also noted that trends in the data suggested that the locally-
released CDA may reduce the clinical signs of gingival inflammation. 
Patients with deficient immune responses are susceptible to destructive and 
necrotizing forms of periodontal diseases (Ryder 2002). The long-term goal for the CDA-
EVA mouthguard is the development of a sustained release intraoral delivery system for 
the treatment of human immunodeficiency virus (HIV)-associated oral infections. The 
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phase I trial demonstrated that the CDA-EVA mouthguard was safe for human use. The 
present phase II trial of this study is a single center, 14-week, double-blinded, 
randomized controlled clinical trial. The objectives of the study are to assess the safety of 
the CDA intraoral delivery system in subjects with HIV infection and periodontitis 
(necrotizing ulcerative or chronic) and further, to evaluate the efficacy of adjunctive 
CDA locally administered via an EVA copolymer mouth guard for the treatment of  
periodontitis in HIV subjects.  
  
CHAPTER 2 
MATERIALS AND METHODS 
The present study protocol was approved by the University of North Carolina 
Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill. 
After a baseline examination, HIV subjects were randomized to one of two groups: 1) 
periodontal debridement plus 2.5% CDA-EVA mouthguard (to be worn 12 hours per day 
for 12 weeks), or 2) periodontal debridement plus placebo (EVA copolymer only) 
mouthguard (to be worn 12 hours per day for 12 weeks). The clinical parameters 
evaluated included percent papillary necrosis, pocket depth, clinical attachment level, 
percent bleeding on probing, gingival index and plaque index measured at baseline, 6 and 
12 weeks; intraoral pain assessments at baseline, 1, 3, 6, 9 and 12 weeks. Plaque samples 
and saliva were collected for DNA analysis of oral bacteria (subgingival, buccal mucosa 
and tongue dorsum sites) at baseline, 6 and 12 weeks and quantitation of salivary HIV-1 
load at baseline, 6, and 12 weeks, respectively. At the time of this thesis, plaque and 
salivary samples were not analyzed. The first twelve subjects to enroll participated in a 
pharmacokinetic component of the trial (six HIV subjects randomized to 2.5% CDA- 
EVA mouthguard and six HIV subjects randomized to control EVA mouthguard). For 
these 12 subjects, the following additional procedures were performed at baseline during 
continuation of an inpatient visit: 5 ml of whole blood and 2 ml of whole unstimulated 
saliva were collected prior to dosing (within 15 minutes or immediately prior to insertion 
of the study mouthguard), the randomized study mouthguard was then inserted
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(dosing/time 0) and 5 ml of whole blood was collected 30 minutes, and at 1, 2, 3 and 6, 
12 , and 18 hours post-dosing while 2 ml of whole, unstimulated saliva, was also 
collected at 30 minutes, and at 1, 2, 3, 6, 12 and 18 hours post-dosing. At 12 hours 
(following blood and saliva collections), the study mouth guard was removed. At 24 
hours post-dosing, approximately 5 ml of whole blood and 2 ml of whole, unstimulated 
saliva was collected (from Day 0). The study mouthguard was then re-inserted 
(dosing/time 0 for Day 1) and 5ml whole blood and 2ml unstimulated saliva was 
recollected at 2 hours post-dosing (from time 0 on Day 1). 
Oral plaque samples were collected but were not analyzed at the time of this 
thesis. Samples were collected from subgingival sites (four sites each constituting the 
deepest pocket per quadrant identified at screening), buccal mucosa and tongue dorsum 
using a sterile curette. Samples were placed into a separate Eppendorf tube containing 
150 µl of TE buffer (i.e., subgingival samples will be pooled). Plaque samples are going 
to be quantitatively and qualitatively analyzed for the presence of oral pathogens using 
checkerboard DNA-DNA analysis (Socransky et al. 1998). Briefly, 100 µl of 0.5 M Na 
OH are to be added to each sample vial and the suspensions boiled in a water bath for 5 
minutes. The samples are then neutralized with 800 µl of 5-M ammonium acetate. The 
released DNA is placed into extended slots of a Minislot-30 apparatus (Immunetics, 
Cambridge, MA) concentrated onto a 15 x 15 cm positively charged nylon membrane 
(Boehringer Mannheim, Indianapolis, IN) and fixed to the membrane by cross-linking 
under ultraviolet light. The membranes are pre-hybridized and placed back in a 
Miniblotter 45-device (Immunetics) producing a 30 x 45 checkerboard pattern. The 
membranes are then blocked in buffer containing 1% casein in maleic acid buffer for 1 
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hour. The signals are detected by scanning the membranes at 1000 volts and 200 microns 
using a Storm Fluorimager (Molecular Dynamics, CA). The signals of the samples are 
converted to absolute counts by comparison with the standard lanes from the membrane. 
A total of 24 different strains will be analyzed at a sensitivity of 103 cells including total 
viable counts (TVD) of each sample. The tested strains include both periodontal and non-
periodontal species (P. gingivalis, P. intermedia, P. nigrescens, B. forsythia, T. denticola, 
A. actinomycetemcomitans, C. rectus, E. corrodens, F. nucleatum, P. micros, C. 
ochracea, V. parvula, S. intermedius, S. oralis, S. sanguis, B. ureolyticus, G. vaginalis, 
M. curtisii, P. bivia, L. crispatus, L. acidophilus, A. viscosis, S. noxia and H. pylori). 
Analyses will include DNA techniques using whole chromosomal and oligonucleotide 
probes. Total organisms will be estimated using an oligonucleotide “universal” probe to 
conserved regions of bacterial 16S rRNA. 
Whole unstimulated saliva (2 ml) was collected by expectoration and processed 
on ice within 2 hrs. Samples were stored at -80°C at the time of this report until analysis. 
Salivary HIV-1 RNA will be quantitated by the nucleic acid sequence-based (NASBA) 
NuclisensTm assay (Shugars et al. 2001). 
At screening and Week 12, peripheral blood and urine samples were collected for 
laboratory assessments. Tests with abnormal, clinically significant values as judged by 
the study physician were repeated to rule out laboratory error. Peripheral blood 
(approximately 5ml sample) was analyzed for protein, bilirubin (total), alkaline 
phosphatase, lactate dehydrogenase, alanine transaminase, aspartate transaminase, blood 
urea, creatinine and serum electrolytes. In addition, a complete blood count (CBC) was 
performed to quantify hemoglobin, hematocrit, white blood cells including differential, 
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and platelets. Females of childbearing potential underwent urine pregnancy testing at 
baseline. Urine samples were analyzed (i.e., urinalysis with dip stick) for glucose, 
protein, pH and specific gravity. 
Blood for pharmacokinetic plasma measurements was collected in appropriate 
containers (i.e., Vacutainer SST tubes). Blood collection tubes were prelabeled with the 
study number, subject number and the time of the sample. Five milliliters (5 ml ± 2 ml) 
of whole blood was collected for each pharmacokinetic sample. Once collected, blood 
samples were rocked gently to mix blood with the anticoagulant, and within 90 minutes 
were centrifuged at 4,400 RPM for 20 minutes. The harvested plasma was transferred to a 
fresh, labeled, screw top polypropylene tube and immediately stored at -80°C or below 
until analysis. For each sample, the subject number, accession number, date, and exact 
time of the sample was recorded on the appropriate case report form. An explanation was 
provided for any sample where the volume deviated by more than 2 ml. At the time of 
this thesis, blood samples for pharmacokinetic evaluation were not as yet analyzed. 
Plasma is to be analyzed for chlorhexidine diacetate concentrations using a high pressure 
liquid chromatography (HPLC) method validated at the appropriate quantitation level 
(Soskolne et al. 1998). 
Whole, unstimulated saliva was collected via expectoration into a pre-labeled and 
pre-weighed vial every 60 seconds until an approximate volume of 2 ml was obtained per 
timed sample. Saliva samples (identified by study number, sample accession number) 
were immediately stored at -80°C or below until analysis. For each sample, the subject 
number, accession number, date, and exact time of the sample was recorded on the 
appropriate case report form. Saliva will be analyzed for chlorhexidine diacetate 
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concentrations using a high pressure liquid chromatography (HPLC) method validated at 
the appropriate quantitation level (Soskolne et al. 1998). 
Baseline and demographic data will be summarized using descriptive statistics. 
Changes in clinical probing parameters (baseline to Weeks 6 and 12) will be expressed as 
mean (or median) values or severity scores per subject. Adverse events and oral soft 
tissue findings were summarized for the eleven evaluated subjects. Inter-group 
differences in mean (median) clinical and microbial values will be tested with t-tests for 
normally distributed values versus Kruskal Wallis tests for non-normally distributed 
values.  
 
 
 
 
 
  
CHAPTER 3 
RESULTS 
At the time of this thesis, eleven subjects have completed the trial to date having 
been dosed with either a 2.5% chlorhexidine diacetate mouthguard or placebo 
mouthguard. Five potential subjects have undergone telephone screenings out of which 4 
subjects have agreed to participate in the trial and have signed informed consent forms. 
From the eleven subjects that have completed the trial, clinical measures, bacterial, blood, 
urine and salivary samples have been collected. Further, subject diaries have been 
evaluated and all adverse events have been recorded. The blind has not been broken at the 
time of this thesis in lieu of an incomplete recruitment process.  
Clinical chemistries from hematological and urine samples demonstrated no 
alterations from baseline (data not shown). Forty AEs have been recorded amongst the 11 
dosed subjects. Thirty-eight were classified as Grade 1 while two AE were classified as 
Grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE). 
The reported AEs for each study subject are presented in Table 4 which indicates the date 
of AE reporting, AE description, possible relation to the study mouthguard, the date of 
AE resolution and the Grade of the AE according to the CTCAE. 
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Table 4: Reported adverse events by participating study subjects. 
Subject 
Number 
Starting 
Date Description 
Relation to 
drug Treatment 
Date 
Resolved 
Adverse 
Event 
Grade 
(CTCAE 
scale) 
2001 
6-13-08 Hyperkeratosis 
Not 
related-
patient 
reported 
trauma 
None 7-25-08 1 
7-7-08 
Traumatized 
incisive 
papilla 
Not 
related-
patient 
reported 
trauma 
None 7-25-08 1 
7-25-08 Hematoma 
Unlikely 
related-
appeared 
to be from 
trauma 
None 8-15-08 1 
8-15-08 Ulceration 
Unlikely 
related-
appeared 
to be from 
trauma 
None 8-21-08 1 
8-12-08 
Patient 
reported 
seizure 
Not 
related-
subject’s 
physician 
believes 
the event 
to be viral  
None 8-19-08 2 
2002 
8-21-08 Nodule 
Unlikely 
related-
appeared 
to be from 
trauma 
None 9-15-08 1 
9-29-08 Ulceration 
Not 
related-
patient 
reported 
trauma 
None 11-5-08 1 
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Subject 
Number 
Starting 
Date Description 
Relation to 
drug Treatment 
Date 
Resolved 
Adverse 
Event 
Grade 
(CTCAE 
scale) 
2003 
10-30-08 
Ulceration-
buccal 
mucosa 
Not 
related-
patient 
reported 
trauma 
None 11-17-08 1 
12-8-08 Sensitive Teeth 
Unlikely 
related-
patient has 
generalized 
gingival 
recession  
Subject was 
treated with 
Gluma 
desensitizing 
agent on 
12-22-08 
12-22-08 1 
2004 
9-19-08 Headache Unlikely 
related 
Subject 
took 600 
mg 
Ibuprofen 
9-21-08 1 
9-29-08 Ulceration 
Unlikely 
related-
appeared 
to be from 
trauma 
None 10-9-08 1 
10-9-08 
Gingival 
inflammation
-subject 
reported 
spontaneous 
bleeding 
Not 
related-
severe 
inflammation
heavy 
plaque 
deposits 
Study 
personnel 
reviewed 
Oral 
Hygiene 
Instructions 
10-30-08 1 
10-9-08 Ulceration 
Unlikely 
related-
appeared 
to be from 
trauma 
None 10-30-08 1 
11-19-08 
Large red 
area on hard 
palate-no 
pain 
Unlikely 
related-
appeared 
to be from 
trauma 
Study 
personnel 
reviewed 
Oral 
Hygiene 
Instructions 
12-8-08 1 
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Subject 
Number 
Starting 
Date Description 
Relation to 
drug Treatment 
Date 
Resolved 
Adverse 
Event 
Grade 
(CTCAE 
scale) 
2005 
11-14-08 
Gingiva 
tender to 
palpation 
Unlikely 
related None 11-25-08 1 
11-22-08 Sore mouth Likely 
related 
Subject did 
not wear 
mouthguard 
for 3 days 
11-25-08 1 
11-25-08 Ulceration 
Unlikely 
related-
appeared 
to be from 
trauma 
None 12-19-08 1 
11-25-08 Ulceration 
Unlikely 
related-
appeared 
to be from 
trauma 
None 12-19-08 1 
12-1-08 Sore Mouth Likely 
related None 12-2-08 1 
12-19-08 Gingival 
edema 
Probably 
not related None 1-9-09 1 
1-1-09 
Gingiva 
tender to 
palpation 
and possible 
tissue 
sloughing 
Likely 
related None 1-3-09 1 
1-8-09 Sinus Infection Not related 
Subject 
took Alka 
Seltzer 
Cold 
1-12-09 1 
1-9-09 Palpable lymph node Not related 
Subject 
took Alka 
Seltzer 
Cold 
1-12-09/ 
1-30-09 1 
1-9-09 
Erythematous 
soft palate 
and uvula 
Not related 
Subject 
took Alka 
Seltzer 
Cold 
1-12-09/ 
1-30-09 1 
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Subject 
Number 
Starting 
Date Description 
Relation to 
drug Treatment 
Date 
Resolved 
Adverse 
Event 
Grade 
(CTCAE 
scale) 
2006 
11-13-08 Ulceration 
Not 
related-
patient had 
not been 
dosed 
None 11-19-08 1 
11-19-08 Ulceration 
Unlikely 
related-
appeared 
to be from 
trauma 
None 12-22-08 1 
12-22-08 Gingival petechiae 
Unlikely 
related None 1-12-09 1 
2007 
11-13-08 Ulceration 
Not 
related-
patient 
reported 
trauma 
None 11-19-08 1 
12-4-08 Ulceration Unlikely 
related None 12-5-08 1 
1-3-09 Cold Not related 
Over the 
counter 
cold 
medicine 
(Robitussin
Mucinex) 
1-7-09 1 
1-12-09 Ulceration 
Not 
related-
patient 
reported 
trauma 
None 2-4-09 1 
2008 
 
11-18-08 Ulceration 
Not 
related-
patient 
reported 
trauma 
None 11-25-08 1 
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Subject 
Number 
Starting 
Date Description 
Relation to 
drug Treatment 
Date 
Resolved 
Adverse 
Event 
Grade 
(CTCAE 
scale) 
 
 
2008 1-22-09 
Swollen 
lymph 
glands 
(sublingual) 
and tonsils 
Unlikely 
related None 
Patient 
still 
enrolled 
in study; 
will 
follow-up 
at next 
appointm
ent 
1 
2009 
11-20-08 Ulceration 
Not 
related-
patient 
reported 
trauma 
None 11-25-08 1 
11-30-08 
Facial 
abcess 
(Methicillin 
Resistant     
S. aureus) 
 
Not 
related-
physician 
diagnosed 
Methicillin 
Resistant     
S. aureus 
Subject’s 
physician 
prescribed 
800 mg 
Bactrim DS-
subject 
discontinued 
from study 
due to 
antibiotic 
use 
12-30-08 2 
 
2010 11-6-08 
Gingival 
Irritation 
Not 
related-
patient had 
not been 
dosed 
None 11-13-08 1 
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Subject 
Number 
Starting 
Date Description 
Relation to 
drug Treatment 
Date 
Resolved 
Adverse 
Event 
Grade 
(CTCAE 
scale) 
 
 
 
 
 
 
2010 
11-25-08 
Bone 
spicule from 
previous 
extraction in 
gingiva 
(tooth was 
extracted 
and site had 
fully healed 
prior to 
enrollment) 
Not related 
Removed 
with cotton 
pliers 
11-25-08 1 
12-15-08 
Pain in 
mandible 
(extraoral 
and intraoral 
exams 
within 
normal 
limits/could 
not find 
cause for 
pain) 
Unlikely 
related None 1-26-09 1 
2012 
12-3-08 Sensitive Teeth 
Not 
related-
gingival 
recession 
and patient 
had not 
been dosed 
None 12-15-08 1 
12-29-08 
Floor of 
mouth 
tender to 
palpation 
Unlikely 
related None 1-23-09 1 
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        The two Grade 2 AEs were facial abscess and seizure and were deemed “not 
related” to the study mouthguard. The subject experiencing the facial abscess (Subject 
Number 2009 in Table 4) was treated by his physician with an antibiotic regimen and was 
subsequently withdrawn from the study while the patient experiencing the seizure 
(Subject Number 2001 in Table 4) persisted in the study until completion with no further 
AEs. The other 38 AEs were categorized as Grade 1. Of the 40 AEs, three were deemed 
“likely related” to the mouthguard. These three lesions occurred in one subject (Subject 
Number 2005) at three different appointments (gingival tenderness to palpation and 
possible tissue sloughing and sore mouth). All other lesions were regarded as “not 
related” or “unlikely related” to the study mouthguard. The most frequently reported AEs 
were oral lesions. There were 29 oral lesions reported in the 11 subjects. These included 
ulceration (12 reports), tooth sensitivity (2 reports), gingival irritation (1 report), gingival 
petechiae (1 report), ginigival edema (1 report), hyperkeratosis (1 report), floor of mouth 
tenderness to palpation (1 report), traumatized incisive papilla (1 report), hematoma (1 
report) and nodule (1 report). Extra-oral AEs included headache (1 report) and pain in 
mandible (1 report) and lymphadenopathy (2 reports).Treatment was rendered in three 
cases: bone spiclues were removed from a previous extraction site in one subject (Subject 
Number 2010). One subject’s physician prescribed 800 mg Bactrim DS for a facial 
abscess and the subject was subsequently discontinued from study due to use of 
antibiotics. Another subject was treated with Gluma desensitizing agent for dental 
sensitivity (Subject Number 2003). No treatment was required for any of the other oral 
lesions, and all lesions resolved upon completion of the study. 
              
  
CHAPTER 4 
DISCUSSION 
Forty adverse events (AEs) were recorded in eleven subjects. Thirty-eight AEs 
were  classified as Grade 1 and two as Grade 2 according to the Common Terminology 
Criteria for Adverse Events (CTCAE). The two Grade 2 AEs were facial abscess and 
seizure and were deemed “not related” to the study mouthguard. Of the 38 Grade 1 AEs, 
the most frequently reported AEs were oral lesions. There were 29 oral lesions reported 
in 11 subjects with “ulceration” as the most frequent. Only three of the recorded AEs 
were deemed “likely related” to the mouthguard while 37 of the remaining AEs were 
classified as “not related” or “unlikely related”. The three lesions “likely related” to the 
mouthguard occurred in one subject at 3 different appointments and consisted of gingival 
tenderness to palpation and possible tissue sloughing and sore mouth.  To date, the CDA-
EVA mouthguard has demonstrated to be relatively safe in HIV subjects with periodontal 
disease with regards to patient reported AEs. 
Thirty subjects were in the original study protocol. Nineteen more subjects are 
required to participate in order to achieve the desired sample size that was predetermined 
for this phase II clinical trial of a 2.5% CDA-EVA controlled-release mouthguard. The 
recruitment process has identified five more subjects eligible for the study through 
telephone interviews/screenings out of which four potential subjects have signed 
informed consent forms and are available to commence the study.  
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Based on the reported adverse events and findings from hematological and urine 
sample analyses, the 2.5% CDA-EVA controlled-release mouthguard in the management 
of periodontal disease in subjects affected with HIV demonstrated relative safety in this 
phase II clinical trial. Only three of forty reported adverse events were deemed “related to 
the mouthguard”. No significant changes in blood chemistries, hematology or urinalysis 
occurred during the course of the study (data not shown). Analyses are ongoing with data 
from clinical, pharmacokinetic, microbial and salivary outcomes to be reported in the 
future. Recruitment of subjects meeting the outlined inclusion and exclusion criteria 
proved to be difficult. Subjects were being recruited from the hospital patient pool at the 
University of North Carolina and from the Department of Periodontology at the School of 
Dentistry.  The timeline of the present study was subsequently recessed and at the time of 
this thesis, data from eleven of the desired thirty participants has been presented. The 
blind was not broken for this thesis and the study is currently ongoing.
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